Product Information
WIXELA 250-50 INHUB is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $1.3156 per EA under NDC 00378932132. Its NADAC has been published 376 times since Apr 17, 2019.
Strength
250; 50 ug/1; ug/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378932132
Classification
Generic
Dosage Form
POWDER
Route
RESPIRATORY (INHALATION)
Last Updated
6/17/2026
Active Ingredients
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATEApproval Type
Generic (ANDA)
FDA Application
ANDA208891On Market Since
2/11/2019
Pharmacological Classes
Price Statistics
The NADAC for WIXELA 250-50 INHUB has been published 376 times since Apr 17, 2019, and over the history we have for it it has declined 65.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.3156 per EA |
|---|---|
| All-time high | $3.7960 (May 15, 2019) |
| All-time low | $1.0972 (Apr 17, 2024) |
| 52-week high | $1.4024 |
| 52-week low | $1.3156 |
| Median price | $1.7302 |
| Average price | $1.9188 |
| Largest weekly change | -30.5% (Apr 17, 2024) |
| Weeks tracked | 376 |
| Tracking since | Apr 17, 2019 |
Generic Alternatives
The matcher finds 4 NADAC-published products sharing this drug's active ingredient, strength, and dosage form across 4 manufacturers (up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of WIXELA 250-50 INHUB?
The current National Average Drug Acquisition Cost (NADAC) for WIXELA 250-50 INHUB, manufactured by Mylan Pharmaceuticals Inc., is $1.3156 per EA (NDC 00378932132), effective Jun 24, 2026.
How has the price of WIXELA 250-50 INHUB changed over time?
Over the history we have for it, the NADAC for WIXELA 250-50 INHUB has declined 65.3%. It has been tracked across 376 weekly CMS publications since Apr 17, 2019.
What are the highest and lowest recorded NADAC prices for WIXELA 250-50 INHUB?
Since Apr 17, 2019, the NADAC for WIXELA 250-50 INHUB has ranged from a low of $1.0972 (Apr 17, 2024) to a high of $3.7960 (May 15, 2019), with a median of $1.7302 per EA.
Are there cheaper alternatives to WIXELA 250-50 INHUB?
4 NADAC-published products share the same active ingredient, strength, and dosage form as WIXELA 250-50 INHUB, but none are currently priced below it.
Who manufactures WIXELA 250-50 INHUB?
WIXELA 250-50 INHUB (NDC 00378932132) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.
Related Drugs
Same classification